Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of rTMS of the Dorsolateral Prefrontal Cortex on Language Production in Healthy Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02840396
Recruitment Status : Completed
First Posted : July 21, 2016
Last Update Posted : October 9, 2019
Sponsor:
Collaborator:
University Hospital Inselspital, Berne
Information provided by (Responsible Party):
Jean-Marie Annoni, University of Fribourg

Brief Summary:
The purpose of this study is to investigate the effects of repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex (DLPFC) on language production.

Condition or disease Intervention/treatment Phase
Language Device: rTMS Device: Sham rTMS Not Applicable

Detailed Description:

Background:

Several studies investigating healthy or clinical populations have shown that (r)TMS applied over the dorsolateral prefrontal cortex (DLPFC) has an effect on language-related processes such as verbal working memory (Osaka et al., 2007), sentence comprehension (Cotelli et al., 2011) and language switching (Holtzheimer et al., 2005, Nardone et al., 2011).

Clinical observations and neuroimaging studies seem to confirm the role of executive functions and frontal structures in language processing in monolingual and bilingual subjects (e.g. Fabbro et al., 2000, Abutalebi & Green 2007). However, only few studies investigated the effects of modulation of cognitive control-networks on lexical access.

Aim and procedure:

The study will investigate the role of the DLPFC and executive functioning in L1 and L2 language processing. The core question is whether rTMS over the DLPFC will influence lexical access and language production.

Each participant will take part in two sessions: 1. rTMS session 2. Sham rTMS session. After the application of rTMS/Sham rTMS, the participants will conduct two language tasks (translation, picture naming) and a non-verbal task, while the EEG is recorded.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Other
Official Title: Role of Executive Function in Language: an Experimental and Clinical Approach With Application to Mother Language and Second Language
Study Start Date : March 2016
Actual Primary Completion Date : June 2017
Actual Study Completion Date : July 2017

Arm Intervention/treatment
Experimental: rTMS Device: rTMS
repetitive TMS (rTMS) can lead to temporary increases or decreases (depending on the protocol used) in excitability of the targeted area. This change in excitability has been shown to last beyond the duration of the stimulation.

Sham Comparator: Sham rTMS Device: Sham rTMS
Sham rTMS (or placebo rTMS) refers to a control condition in which no physiological effect on the targeted cortical region occurs.




Primary Outcome Measures :
  1. Language production [ Time Frame: within 30 mins after rTMS/sham rTMS ]
    Picture naming task and word translation task


Secondary Outcome Measures :
  1. non-verbal executive functions task [ Time Frame: within 30 mins after rTMS/sham rTMS ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • L1 French, knowledge of English as a foreign language
  • 18-45 years of age
  • Right-handedness

Exclusion Criteria:

  • epilepsy /family history of epilepsy
  • brain surgery, traumatic brain injuries
  • cardiac pacemaker, metallic objects in the body
  • history of neurological diseases or psychiatric disorders
  • drug use (alcohol, psychoactive medication)
  • developmental language disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02840396


Locations
Layout table for location information
Switzerland
Laboratory for Cognitive and Neurological Sciences
Fribourg, Switzerland, 1700
Sponsors and Collaborators
Jean-Marie Annoni
University Hospital Inselspital, Berne
Investigators
Layout table for investigator information
Principal Investigator: Jean-Marie Annoni, Prof. Dr. University of Fribourg
Publications:
Layout table for additonal information
Responsible Party: Jean-Marie Annoni, Prof. Dr. med., University of Fribourg
ClinicalTrials.gov Identifier: NCT02840396    
Other Study ID Numbers: SNF325130_156937_2
First Posted: July 21, 2016    Key Record Dates
Last Update Posted: October 9, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Jean-Marie Annoni, University of Fribourg:
language
DLPFC
rTMS
Executive Functions